FCA
ORIC icon

FinTrust Capital Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

FinTrust Capital Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$1K – 1283
2022
Q1 		$1K Buy
+100
New +$901 ﹤0.01% 1181

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

FinTrust Capital Advisors's ORIC Position: Q2 2022 in Review

FinTrust Capital Advisors sold out of Oric Pharmaceuticals (ORIC) in Q2 2022, closing a stake of 100 shares — an estimated $1K sold.

FinTrust Capital Advisors first reported a position in ORIC in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 83 funds tracked by Wall St. Rank hold ORIC as of Q2 2022.

  • FinTrust Capital Advisors reported no remaining Oric Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • FinTrust Capital Advisors sold 100 Oric Pharmaceuticals shares in Q2 2022, an estimated $1K.
  • FinTrust Capital Advisors first reported a position in Oric Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • FinTrust Capital Advisors's Oric Pharmaceuticals position peaked at $1K in Q1 2022.
  • 83 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2022.

Based on FinTrust Capital Advisors's 13F filing for Q2 2022, filed 26 Jul 2022.